PL2621481T3 - Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości - Google Patents

Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości

Info

Publication number
PL2621481T3
PL2621481T3 PL11764655T PL11764655T PL2621481T3 PL 2621481 T3 PL2621481 T3 PL 2621481T3 PL 11764655 T PL11764655 T PL 11764655T PL 11764655 T PL11764655 T PL 11764655T PL 2621481 T3 PL2621481 T3 PL 2621481T3
Authority
PL
Poland
Prior art keywords
castration
vegf
met
treatment
prostate cancer
Prior art date
Application number
PL11764655T
Other languages
English (en)
Other versions
PL2621481T5 (pl
Inventor
David Smith
Maha Hussain
Original Assignee
Exelixis, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44741730&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2621481(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Exelixis, Inc. filed Critical Exelixis, Inc.
Publication of PL2621481T3 publication Critical patent/PL2621481T3/pl
Publication of PL2621481T5 publication Critical patent/PL2621481T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C07D215/22—Oxygen atoms attached in position 2 or 4

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Peptides Or Proteins (AREA)
PL11764655.4T 2010-09-27 2011-09-26 Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości PL2621481T5 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US38695910P 2010-09-27 2010-09-27
US201161481671P 2011-05-02 2011-05-02
PCT/US2011/053233 WO2012044572A1 (en) 2010-09-27 2011-09-26 Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
EP11764655.4A EP2621481B2 (en) 2010-09-27 2011-09-26 Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastases

Publications (2)

Publication Number Publication Date
PL2621481T3 true PL2621481T3 (pl) 2020-03-31
PL2621481T5 PL2621481T5 (pl) 2023-03-13

Family

ID=44741730

Family Applications (1)

Application Number Title Priority Date Filing Date
PL11764655.4T PL2621481T5 (pl) 2010-09-27 2011-09-26 Podwójne inhibitory MET i VEGF do leczenia opornego na kastrację raka prostaty i osteoblastycznych przerzutów do kości

Country Status (22)

Country Link
US (5) US20140057943A1 (pl)
EP (1) EP2621481B2 (pl)
JP (2) JP6158705B2 (pl)
KR (1) KR101882328B1 (pl)
CN (1) CN103402505A (pl)
AR (1) AR085195A1 (pl)
AU (2) AU2011307304C1 (pl)
BR (1) BR112013007220A2 (pl)
CA (1) CA2812750C (pl)
DK (1) DK2621481T4 (pl)
EA (1) EA027476B1 (pl)
ES (1) ES2754973T5 (pl)
FI (1) FI2621481T4 (pl)
HU (1) HUE045810T2 (pl)
IL (1) IL225507B (pl)
MX (1) MX352926B (pl)
PL (1) PL2621481T5 (pl)
PT (1) PT2621481T (pl)
SI (1) SI2621481T2 (pl)
TW (2) TW201738213A (pl)
UA (1) UA114172C2 (pl)
WO (1) WO2012044572A1 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX336741B (es) 2010-07-16 2016-01-29 Exelixis Inc Composiciones farmaceuticas de moduladores de c-met.
WO2012044572A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
JP2014505109A (ja) 2011-02-10 2014-02-27 エクセリクシス， インク． キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) * 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
EP2776033A1 (en) * 2011-11-08 2014-09-17 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
CN103664776B (zh) * 2012-09-26 2016-05-04 正大天晴药业集团股份有限公司 一种酪氨酸激酶抑制剂及其中间体的制备方法
NZ712330A (en) 2013-03-15 2020-04-24 Exelixis Inc Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
AU2014248001A1 (en) * 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer
US11564915B2 (en) 2013-04-04 2023-01-31 Exelixis, Inc. Cabozantinib dosage form and use in the treatment of cancer
MX2021001583A (es) 2014-02-14 2023-02-08 Exelixis Inc Formas sólidas cristalinas de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi ] fenil}-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida, procesos para elaboración y métodos de uso.
EP3119476A1 (en) 2014-03-17 2017-01-25 Exelixis, Inc. Dosing of cabozantinib formulations
CN104788372B (zh) * 2014-07-25 2018-01-30 上海圣考医药科技有限公司 一种氘代卡博替尼衍生物、其制备方法、应用及其中间体
WO2016019285A1 (en) 2014-07-31 2016-02-04 Exelixis, Inc. Method of preparing fluorine-18 labeled cabozantinib and its analogs
US11065240B2 (en) 2014-08-05 2021-07-20 Exelixis, Inc. Drug combinations to treat multiple myeloma
KR20170108822A (ko) * 2016-03-18 2017-09-27 니혼 메디피직스 가부시키가이샤 조골형 골전이 모델 동물의 제조 방법
MA44672A (fr) 2016-04-15 2019-02-20 Exelixis Inc Procédé de traitement du cancer à cellules rénales à l'aide de n-(4-(6,7-diméthoxyquinolin-4-yloxy) phényl)-n'-(4-fluorophény)cyclopropane-1,1-dicarboxamide, (2s)-hydroxybutanedioate
CN108503650B (zh) * 2017-02-27 2021-02-12 北京赛特明强医药科技有限公司 二噁烷并喹唑啉类化合物或其药用盐或其水合物及其作为酪氨酸激酶抑制剂的应用
MA48776A (fr) 2017-05-26 2020-04-08 Exelixis Inc Formes solides cristallines de sels de n-{4-[(6,7-diméthoxyquinolin-4-yl) oxy]phényl}-n'-(4-fluorphényl) cyclopropane-1,1-dicarboxamide, procédés de préparation et d'utilisation
US11547709B2 (en) 2017-12-27 2023-01-10 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor
KR20200130242A (ko) 2017-12-27 2020-11-18 세인트 쥬드 칠드런즈 리써치 호스피탈, 인코포레이티드 판토테네이트 키나제의 소분자 조절제
CN117820226A (zh) 2018-01-26 2024-04-05 埃克塞里艾克西斯公司 用于治疗激酶依赖性病症的化合物
KR102433023B1 (ko) * 2018-02-11 2022-08-16 베이징 사이텍-엠큐 파마슈티컬즈 리미티드 디옥시노퀴놀린 화합물, 이의 제조방법 및 용도
EP4262814A1 (en) * 2020-12-16 2023-10-25 St. Jude Children's Research Hospital, Inc. Methods of treating disorders associated with castor

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
EP1447405A4 (en) 2001-10-17 2005-01-12 Kirin Brewery QUINOLINE OR QUINAZOLINE DERIVATIVES INHIBITING THE AUTOPHOSPHORYLATION OF FIBROBLAST GROWTH FACTOR RECEPTORS
GB0219746D0 (en) 2002-08-23 2002-10-02 Inst Of Ex Botany Ascr Azapurine derivatives
ES2294317T3 (es) 2002-10-21 2008-04-01 Kirin Pharma Kabushiki Kaisha Sal de n-(2-cloro-4-((6,7-dimetoxi-4-quinolil)oxi)fenil)-n'-(5-metil-3-isoxazolil)urea de forma cristalina.
US20080207617A1 (en) 2002-10-29 2008-08-28 Kirin Beer Kabushiki Kaisha Quinoline Derivatives and Quinazoline Derivatives Inhibiting Autophosphrylation of Flt3 and Medicinal Compositions Containing the Same
RU2350618C2 (ru) 2002-11-04 2009-03-27 Астразенека Аб ПРОИЗВОДНЫЕ ХИНАЗОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Src ТИРОЗИНКИНАЗЫ
EP1569926A1 (en) 2002-12-13 2005-09-07 Neurogen Corporation Carboxylic acid, phosphate or phosphonate substituted quinazolin-4-ylamine analogues as capsaicin receptor modulators
EP1575592A1 (en) 2002-12-18 2005-09-21 Pfizer Products Inc. 4-anilino quinazoline derivatives for the treatment of abnormal cell growth
EP1575591A4 (en) 2002-12-23 2007-09-12 Ariad Pharma Inc HETEROCYCLES AND ITS USE
AU2003292838A1 (en) 2002-12-27 2004-07-29 Kirin Beer Kabushiki Kaisha Therapeutic agent for wet age-related macular degeneration
ES2371383T3 (es) 2003-09-26 2011-12-30 Exelixis, Inc. N-[3-fluoro-4-({6-(metiloxi)-7-[(3-morfolin-4-ilpropil)oxi]quinolin-4-il}oxi)fenil]-n'-(4-fluorofenil)ciclopropan-1,1-dicarboxamida para el tratamiento del cáncer.
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
WO2006108059A1 (en) 2005-04-06 2006-10-12 Exelixis, Inc. C-met modulators and methods of use
US20080004273A1 (en) 2006-05-30 2008-01-03 Stephane Raeppel Inhibitors of protein tyrosine kinase activity
WO2008076415A1 (en) 2006-12-14 2008-06-26 Exelixis, Inc. Methods of using mek inhibitors
WO2008083319A1 (en) 2006-12-29 2008-07-10 Il Yang Pharmaceutical Company, Ltd. Solid state forms of enantiopure ilaprazole
BRPI0816064B8 (pt) * 2007-08-29 2021-05-25 Methylgene Inc composto inibidor da atividade de proteína tirosina quinase, seu uso, e composição farmacêutica
TW200922590A (en) * 2007-09-10 2009-06-01 Curis Inc VEGFR inhibitors containing a zinc binding moiety
UY31800A (es) 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
MX2010012290A (es) * 2008-05-14 2011-02-21 Amgen Inc Combinaciones de inhibidores del receptor del factor de crecimiento endotelial vascular e inhibidores del factor de crecimiento de hepatocito para el tratamiento de cancer.
AR075084A1 (es) 2008-09-26 2011-03-09 Smithkline Beecham Corp Metodo de preparacion de quinolinil -oxidifenil - ciclopropanodicarboxamidas e intermediarios correspondientes
MX2011003363A (es) 2008-10-01 2011-04-27 Ludwig Inst Cancer Res Metodos para el tratamiento de cancer.
MX2011005038A (es) 2008-11-13 2011-06-16 Exelisis Inc Metodo de preparacion de derivados de quinolina.
JP2010126530A (ja) * 2008-12-01 2010-06-10 Takeda Chem Ind Ltd 縮合複素環誘導体およびその用途
TW201028383A (en) 2008-12-04 2010-08-01 Exelixis Inc Methods of preparing quinoline derivatives
TW202241853A (zh) 2009-01-16 2022-11-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
WO2011009095A1 (en) 2009-07-17 2011-01-20 Exelixis, Inc. Crystalline forms of n-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-quin0lin-4-yl}oxy)phenyl]-n'-(4-fluorophenyl)cyclopropane-1, 1-dicarboxamide
UA108618C2 (uk) 2009-08-07 2015-05-25 Застосування c-met-модуляторів в комбінації з темозоломідом та/або променевою терапією для лікування раку
WO2011031840A1 (en) 2009-09-09 2011-03-17 Quintiles Transnational Corp. Methods and compositions for the treatment of receptor tyrosine kinase mediated diseases or disorders
US20130143881A1 (en) 2010-03-12 2013-06-06 Exelixis, Inc. Hydrated Crystalline Forms of N-[3-fluoro-4-(oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
US20120070368A1 (en) 2010-04-16 2012-03-22 Exelixis, Inc. Methods of Using C-Met Modulators
WO2012009723A1 (en) 2010-07-16 2012-01-19 Exelixis, Inc. C-met modulator pharmaceutical compositions
MX336741B (es) 2010-07-16 2016-01-29 Exelixis Inc Composiciones farmaceuticas de moduladores de c-met.
WO2012044572A1 (en) * 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration- resistant prostate cancer and osteoblastic bone metastases
JP2013540759A (ja) 2010-09-27 2013-11-07 エクセリクシス， インク． 去勢抵抗性前立腺癌および造骨性転移の治療のためのｍｅｔおよびｖｅｇｆの二元阻害薬
US20140057908A1 (en) 2010-09-27 2014-02-27 Exelixis, Inc. Method of Treating Cancer
US20130252956A1 (en) 2010-11-22 2013-09-26 Howard Kallender Methods of treating cancer
JP2014505109A (ja) 2011-02-10 2014-02-27 エクセリクシス， インク． キノリン化合物およびそのような化合物を含有する医薬組成物の調製方法
US20120252840A1 (en) 2011-04-04 2012-10-04 Exelixis, Inc. Method of Treating Cancer
GEP201706678B (en) 2011-05-02 2017-06-12 Exelixis Inc Method of treating cancer and bone cancer
TW201306842A (zh) 2011-06-15 2013-02-16 Exelixis Inc 使用ｐｉ３ｋ／ｍｔｏｒ吡啶並嘧啶酮抑制劑及苯達莫司汀及／或利妥昔單抗治療惡性血液疾病之組合療法
MX351133B (es) 2011-09-22 2017-10-03 Exelixis Inc Metodo para tratar osteoporosis.
CA2852771C (en) 2011-10-20 2019-11-26 Exelixis, Inc. Process for preparing quinoline derivatives
EP2776033A1 (en) 2011-11-08 2014-09-17 Exelixis, Inc. Dual inhibitor of met and vegf for treating cancer
JP2015515988A (ja) 2012-05-02 2015-06-04 エクセリクシス， インク． 溶骨性骨転移を治療するためのｍｅｔ−ｖｅｇｆ二重調節剤
US20140121239A1 (en) 2012-09-07 2014-05-01 Exelixis, Inc. Method of treating lung adenocarcinoma
US20140221372A1 (en) 2013-02-06 2014-08-07 GlaxoSmithKline Intellectual Property (NO 2.) Limited Method of administration and treatment
NZ712330A (en) 2013-03-15 2020-04-24 Exelixis Inc Metabolites of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide
AU2014248001A1 (en) 2013-04-04 2015-11-19 Exelixis, Inc. Drug combinations to treat cancer

Also Published As

Publication number Publication date
AU2011307304C1 (en) 2016-10-20
DK2621481T4 (da) 2023-01-09
SI2621481T2 (sl) 2023-02-28
EA201390465A1 (ru) 2013-08-30
CA2812750A1 (en) 2012-04-05
CA2812750C (en) 2020-10-06
PL2621481T5 (pl) 2023-03-13
CN103402505A (zh) 2013-11-20
SI2621481T1 (sl) 2019-11-29
DK2621481T3 (da) 2019-10-21
TW201738213A (zh) 2017-11-01
MX2013003594A (es) 2013-08-01
US20140057943A1 (en) 2014-02-27
IL225507B (en) 2019-08-29
AU2011307304A1 (en) 2013-05-02
KR101882328B1 (ko) 2018-07-27
MX352926B (es) 2017-12-14
EP2621481B1 (en) 2019-08-14
WO2012044572A1 (en) 2012-04-05
UA114172C2 (uk) 2017-05-10
ES2754973T3 (es) 2020-04-21
HUE045810T2 (hu) 2020-01-28
BR112013007220A2 (pt) 2017-08-08
US20240156803A1 (en) 2024-05-16
JP2017149714A (ja) 2017-08-31
FI2621481T4 (fi) 2023-01-13
TW201302709A (zh) 2013-01-16
US11969419B2 (en) 2024-04-30
US11612597B2 (en) 2023-03-28
AU2011307304B2 (en) 2016-04-14
JP6158705B2 (ja) 2017-07-05
EP2621481A1 (en) 2013-08-07
IL225507A0 (en) 2013-06-27
US20160220554A1 (en) 2016-08-04
ES2754973T5 (es) 2023-03-13
AR085195A1 (es) 2013-09-18
KR20140025304A (ko) 2014-03-04
PT2621481T (pt) 2019-11-19
AU2016204747A1 (en) 2016-07-28
US20200330450A1 (en) 2020-10-22
US20230301980A1 (en) 2023-09-28
EA027476B1 (ru) 2017-07-31
EP2621481B2 (en) 2022-10-19
JP2013537916A (ja) 2013-10-07

Similar Documents

Publication Publication Date Title
IL225507A0 (en) Dual inhibitors of met and vegf for the treatment of castration-resistant prostate cancer and osteoblastic bone metastasis
IL276362A (en) Cancer treatment methods
HK1202062A1 (en) Dual inhibitor of met and vegf for treating cancer met vegf
SG10201508495VA (en) Combination treatment of cancer
HRP20170225T1 (hr) Fosfoplatini i njihova uporaba za liječenje karcinoma
HK1189272A1 (zh) 治療癌症的方法
EP2640390A4 (en) METHODS OF TREATING CANCER
EP2911692A4 (en) USE OF ENDOCYTOSE INHIBITORS AND ANTIBODIES FOR ANTICANCER THERAPY
EP2635273A4 (en) ISOFLAVONOID COMPOSITIONS AND METHOD FOR CANCER TREATMENT
PT2619331T (pt) Métodos de tratamento de cancro incluindo rastreio de nqo1
EP2547368A4 (en) METHOD AND COMPOSITIONS FOR CANCER TREATMENT
ZA201202379B (en) Antagonists of dsgs2 for treatment of cancer
WO2012037553A9 (en) Use of pkc-iota inhibitors for the treatment of breast cancer
GB201017354D0 (en) Treatment of cancer
GB201017356D0 (en) Combination treatment of cancer
IL221238A0 (en) Pharmaceutical compositions and methods for the treatment and prevention of cancer
HU1000559D0 (en) Pharmaceutical compositions for the treatment of osteoporosis and cancer